Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPT2 | P23786 | 1/20 | 0.51 |
| ▸ | ACLY | P53396 | 1/20 | 0.51 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.51 |
| ▸ | BLM | P54132 | 1/20 | 0.51 |
| ▸ | HSPE1 | P61604 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | NAAA | Q02083 | 1/20 | 0.40 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7860982 | 0.82 | HSPD1 (0.56) | CPT2ACLYHSPD1BLMHSPE1 | |
| SCHEMBL21248068 | 0.82 | HSPD1 (0.60) | HSPD1BLMHSPE1MEN1HPGD | |
| SCHEMBL2463997 | 0.82 | HSPD1 (0.68) | CPT2ACLYHSPD1BLMHSPE1 | |
| SCHEMBL6288812 | 0.81 | HSPD1 (0.71) | HSPD1BLMHSPE1MEN1HPGD | |
| SCHEMBL1218292 | 0.81 | HSPD1 (0.71) | HSPD1BLMHSPE1MEN1HPGD | |
| SCHEMBL1659505 | 0.81 | HSPD1 (0.51) | HSPD1BLMHSPE1MEN1HPGD | |
| SCHEMBL8567937 | 0.80 | HSPD1 (0.50) | HSPD1BLMHSPE1MEN1HPGD | |
| SCHEMBL6050436 | 0.80 | HSPD1 (0.57) | CPT2ACLYHSPD1BLMHSPE1 | |
| SCHEMBL1038854 | 0.79 | HSPD1 (0.53) | CPT2ACLYHSPD1BLMHSPE1 | |
| SCHEMBL2877365 | 0.77 | NAAA (0.46) | MEN1HPGDRECQLKMT2AHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170312200-A1 | AN AGENT FOR IMPROVING MITOCHONDRIAL FUNCTION | SHOWA DENKO K.K. (JP) | 2017-11-02 | — | — | US | disclosed |
| EP-3213739-A1 | AGENT FOR IMPROVING MITOCHONDRIAL FUNCTION AND ANTI-AGING COMPOSITION | Showa Denko K.K. (JP) | 2017-09-06 | — | — | EP | disclosed |
| EP-1799631-B1 | HYDROXYCITRIC ACID DERIVATIVES AND SKIN EXTERNAL PREPARATIONS CONTAINING THE SAME | SHOWA DENKO KK (JP) | 2017-01-25 | — | — | EP | disclosed |
| US-7846970-B2 | Hydroxycitric acid derivatives and skin external preparations containing the same | SHOWA DENKO K.K. (JP) | 2010-12-07 | — | — | US | disclosed |
| US-20070293577-A1 | Hydroxycitric Acid Derivatives And Skin External Preparations Using The Same | SHOWA DENKO K.K. (JP) | 2007-12-20 | — | — | US | disclosed |
| EP-1799631-A1 | HYDROXYCITRIC ACID DERIVATIVES AND SKIN EXTERNAL PREPARATIONS CONTAINING THE SAME | Showa Denko K.K. (JP) | 2007-06-27 | — | — | EP | disclosed |
| WO-2006033476-A1 | HYDROXYCITRIC ACID DERIVATIVES AND SKIN EXTERNAL PREPARATIONS CONTAINING THE SAME | SHOWA DENKO K.K. (JP) | 2006-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170312200-A1 | AN AGENT FOR IMPROVING MITOCHONDRIAL FUNCTION | UQCRC1, ACAD9, CYP27B1 | CPT2 102/4885ACLY 469/4885HSPD1 75/4885 |
| US-20070293577-A1 | Hydroxycitric Acid Derivatives And Skin External Preparations Using The Same | HAAO, CYP8B1, CUTA | CPT2 1057/4885ACLY 1171/4885HSPD1 271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.